BACKGROUND: The existence of Epstein-Barr virus (EBV) strains specifically associated with multiple sclerosis (MS) is a matter of controversy. Little is also known about the prevalence of EBV types 1 and 2 in MS patients and the presence of co-infections by both strains. OBJECTIVE: To make EBV strain type assignment and compare the frequencies of types 1, 2 and co-infections by both in MS patients and healthy controls. METHODS: Blood samples from 75 consecutive MS patients and 186 controls were collected. EBV was simultaneously detected and typed using a polymerase chain reaction (PCR) which amplified a strain-specific sequence in the EBV nuclear antigen 2. RESULTS: EBV was detected in 70 out of 75 patients (93.3%) and in 123 of 186 controls (66.1%). Among positive cases, type 1 was found in 6 patients (8.6%) and 40 controls (32.5%), type 2 in 1 patient (1.4%) and 37 controls (30.1%), and dual-infections by both EBV types were detected in 63 patients (90%) and 46 controls (37.4%). Logistic regression models showed that MS was significantly associated with the presence of EBV (p < 0.001) and also with dual type infections (p < 0.001). CONCLUSION: This study provides molecular evidence associating co-infection of type 1 and 2 EBV with MS.
BACKGROUND: The existence of Epstein-Barr virus (EBV) strains specifically associated with multiple sclerosis (MS) is a matter of controversy. Little is also known about the prevalence of EBV types 1 and 2 in MSpatients and the presence of co-infections by both strains. OBJECTIVE: To make EBV strain type assignment and compare the frequencies of types 1, 2 and co-infections by both in MSpatients and healthy controls. METHODS: Blood samples from 75 consecutive MSpatients and 186 controls were collected. EBV was simultaneously detected and typed using a polymerase chain reaction (PCR) which amplified a strain-specific sequence in the EBV nuclear antigen 2. RESULTS:EBV was detected in 70 out of 75 patients (93.3%) and in 123 of 186 controls (66.1%). Among positive cases, type 1 was found in 6 patients (8.6%) and 40 controls (32.5%), type 2 in 1 patient (1.4%) and 37 controls (30.1%), and dual-infections by both EBV types were detected in 63 patients (90%) and 46 controls (37.4%). Logistic regression models showed that MS was significantly associated with the presence of EBV (p < 0.001) and also with dual type infections (p < 0.001). CONCLUSION: This study provides molecular evidence associating co-infection of type 1 and 2 EBV with MS.
Authors: Carmen Yea; Raymond Tellier; Patrick Chong; Garrett Westmacott; Ruth Ann Marrie; Amit Bar-Or; Brenda Banwell Journal: Neurology Date: 2013-09-06 Impact factor: 9.910
Authors: Rosella Mechelli; Caterina Manzari; Claudia Policano; Anita Annese; Ernesto Picardi; Renato Umeton; Arianna Fornasiero; Anna Maria D'Erchia; Maria Chiara Buscarinu; Cristina Agliardi; Viviana Annibali; Barbara Serafini; Barbara Rosicarelli; Silvia Romano; Daniela F Angelini; Vito A G Ricigliano; Fabio Buttari; Luca Battistini; Diego Centonze; Franca R Guerini; Sandra D'Alfonso; Graziano Pesole; Marco Salvetti; Giovanni Ristori Journal: Neurology Date: 2015-03-04 Impact factor: 9.910
Authors: D Csuka; D Simon; R Hóbor; K Uray; Z Prohászka; Z Bánlaki; P K Jani; Á Szilágyi; F Hudecz; K Rajczy; G Beke; A Boros Major; A Tordai; Z Illés; T Berki; L Czirják; G Füst Journal: Clin Exp Immunol Date: 2013-03 Impact factor: 4.330
Authors: Gabriel Santpere; Fleur Darre; Soledad Blanco; Antonio Alcami; Pablo Villoslada; M Mar Albà; Arcadi Navarro Journal: Genome Biol Evol Date: 2014-04 Impact factor: 3.416
Authors: Monika Tschochner; Shay Leary; Don Cooper; Kaija Strautins; Abha Chopra; Hayley Clark; Linda Choo; David Dunn; Ian James; William M Carroll; Allan G Kermode; David Nolan Journal: PLoS One Date: 2016-02-05 Impact factor: 3.240